Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
V. Palatkin
Observed names:
V Palatkin,
V. Ya Palatkin,
V. Ya. Palatkin,
V. Yа. Palatkin,
V.Y. Palatkin,
V.Ya. Palatkin,
Vladimir Palatkin,
Vladimir Y. Palatkin
show all 8
Institution:
First Pavlov State Medical University of St. Petersburg
Observed institutions:
First Pavlov State Medical University of St. Petersburg,
St.Petersburg V.M.Bekhterev Psychoneurological Research Institute,
Treatment Research Institute,
Research Institute of Influenza,
Federal Medical Research Centre for Psychiatry and Narcology,
University of Pennsylvania
show all 6
ORCID:
0000-0003-4100-350X
Observed ORCID:
0000-0003-4100-350X
OpenAlex ID:
A5079734594
Randomized Trial of Long-Acting Sustained-Release Naltrexone Implant vs Oral Naltrexone or Placebo for Preventing Relapse to Opioid Dependence
2012
·
Evgeny Krupitsky
, Edwin Zvartau
, et al.
·
Archives of General Psychiatry
·
156
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant
2016
·
Evgeny Krupitsky
, Edwin Zvartau
, et al.
·
The American Journal of Drug and Alcohol Abuse
·
94
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia
2013
·
Evgeny Krupitsky
, Edwin Zvartau
, et al.
·
Drug and Alcohol Dependence
·
42
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial
2019
·
Evgeny Krupitsky
, Elena Blokhina
, et al.
·
The Lancet HIV
·
21
Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia–A prospective cohort analysis
2022
·
Marina Vetrova
, Sara Lodi
, et al.
·
International Journal of Drug Policy
·
15
PDF
Stabilization of remission in patients with opioid dependence with naltrexone implant: a pharmacogenetic approach
2015
·
Е. М. Krupitsky
, А. О. Kibitov
, et al.
·
S S Korsakov Journal of Neurology and Psychiatry
·
9
A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine
2016
·
А. О. Kibitov
, Е. М. Krupitsky
, et al.
·
S S Korsakov Journal of Neurology and Psychiatry
·
4
Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant
2018
·
E. M. Krupitsky
, E. E. Zvartau
, et al.
·
S S Korsakov Journal of Neurology and Psychiatry
·
3
Stress hormone biomarkers and cognitive functions among HIV-positive patients with opioid use disorder
2022
·
M.V. Vetrova
, V.Ya. Palatkin
, et al.
·
Infectious diseases News Opinions Training
·
2
PDF
P.3.011 Risk factors for suicidal ideation among HIV-infected drinkers in Russia
2012
·
T. Yaroslavtseva
, E. Krupitsky
, et al.
·
European Neuropsychopharmacology
·
2
P.6.012 Analysis of the impact of different forms of naltrexone on the syndrome of anhedonia and depression among heroin addicts
2011
·
A. Tiurina
, E. Krupitsky
, et al.
·
European Neuropsychopharmacology
·
2
Genetic and Pharmacogenetic Aspects of Opioid Use Disorder
2021
·
E.A. Blokhina
, V.Ya. Palatkin
, et al.
·
Вопросы наркологии
·
1
P.443 Does alcohol use provoke relapse in patients with opioid use disorder stabilized on naltrexone?
2019
·
V. Palatkin
, E. Krupitsky
, et al.
·
European Neuropsychopharmacology
·
1
Use of nalmefene and behavioral counseling in patients with combined opioid and alcohol dependence
2025
·
Marina V. Vetrova
, Elena A. Blokhina
, et al.
·
Neurology Bulletin
PDF
Opioid Withdrawal Syndrome: Neurobiological, Clinical and Pharmacological Aspects (a Literature Review)
2021
·
M.V. Vetrova
, E.A. Blokhina
, et al.
·
Вопросы наркологии
P.0315 Association between hazardous alcohol use and initiation of naltrexone treatment for opioid use disorder among hiv-positive persons in russia
2021
·
M. Vetrova
, E.A. Blokhina
, et al.
·
European Neuropsychopharmacology
P.0319 Clonidine lowers interleukin-6 in people with hiv during opioid withdrawal
2021
·
V. Palatkin
, M. Vetrova
, et al.
·
European Neuropsychopharmacology
Levels of plasma soluble CD14 in HIV-positive patients during opioid withdrawal syndrome
2021
·
A.N. Kholodnaya
, V.Ya. Palatkin
, et al.
·
Infectious diseases News Opinions Training
PDF
P.011 Prospective cohort analysis of dehydroepiandrosterone-sulfate and visuospatial memory during opioids abstinence in HIV-positive people with opioid dependence
2020
·
V. Palatkin
, E. Protsenko
, et al.
·
European Neuropsychopharmacology
P.010 The association between sCD14 and neurocognitive performance during early abstinence among HIV-positive patients in Russia
2020
·
M. Vetrova
, V. Palatkin
, et al.
·
European Neuropsychopharmacology
Slow Release Naltrexone Implant Vs Oral Naltrexone for Improving Treatment Outcomes in Opioid Addicted Patients With Hiv: a Double-blind, Placebo-controlled, Randomized Trial
2020
·
E.M. Krupitsky
, E.A. Blokhina
, et al.
·
Вопросы наркологии
Exploring genetic predictors of naltrexone treatment response in opioid use disorder
2019
·
Е. A. Blokhina .
, E. М. Krupitsky
, et al.
·
V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
PDF
Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect
2019
·
V. Ya Palatkin
, A. O. Kibitov
, et al.
·
V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
PDF
Fatal overdose in recently detoxified Russian HIV-positive persons with opioid use disorder: The role of naltrexone in prevention
2019
·
V. Palatkin
, T. Yaroslavtseva
, et al.
·
European Neuropsychopharmacology
Slow Release Naltrexone Implant vs Oral Naltrexone for Improving Treatment Outcomes in Opioid Addicted Participants with HIV: A Randomised Trial
2018
·
George Woody
, E. Krupitsky
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
35
Citation count:
352
H-index:
6
I10-index:
5
Year
Topic
Type